Canadian Patients Anticipate Generic Ozempic Amid Lack of Drug Coverage

Canadian patients, particularly those without diabetes, are eagerly anticipating the approval of generic Ozempic due to the rising costs associated with the brand-name medication. Ozempic has gained notoriety as a treatment for obesity but is primarily prescribed for diabetes management, creating a gap in accessibility for many Canadians in need.

Challenges in Accessing Ozempic

For individuals like Anne Welch, a 77-year-old retiree from Paris, Ontario, the inability to access Ozempic without a diabetes diagnosis presents a significant hurdle. Despite being recommended the medication to aid in weight loss, she cannot benefit from the Ontario Drug Benefit program, which covers medications for seniors over 65. This program only funds Ozempic for patients diagnosed with diabetes.

• Cost of Ozempic: Often several hundred dollars per month.
• Patients on fixed incomes find it challenging to purchase the medication out-of-pocket.

The Need for Generics

Welch, who has been inspired by her husband’s success with Ozempic, is hopeful that one of the nine generic versions of semaglutide currently under review will receive approval soon. This drug is the active ingredient in Ozempic and would be available at a considerably lower cost than its branded counterpart. According to Mina Tadrous, a pharmaceutical policy expert from the University of Toronto, the pricing structure for generics indicates significant potential savings:

• The first generic medication could cost 75-85% of the brand name.
• With the release of a second generic, prices could drop to around 50%.
• Once three or more generics are available, costs could decrease to approximately 35% of the brand’s price.

Economic Impact of Ozempic

Ozempic has emerged as a leading driver of public prescription drug spending in Canada, accounting for a staggering $807 million of the total $20.1 billion spent on public drugs. The cost continues to be a key obstacle for patients without diabetes seeking GLP-1 medications for weight management.

Hope for Future Approval

Healthcare providers like Dr. Megha Poddar, an endocrinologist at McMaster University, emphasize the importance of introducing generic alternatives to enhance patient access. Canada is expected to be the first nation to authorize generic semaglutide since Novo Nordisk’s patent protection ended last January. This status may change soon, however, as India has already authorized two generic versions, one of which is under review by Health Canada.

Marie-Pier Burelle, a spokesperson for Health Canada, noted that the agency is on track with the review process for these generics, which is expected to take about six months. However, complexities in the process may extend the time needed for approval.

Patient Perspectives

Brenda Rogers, a 53-year-old business manager from Vancouver, is another individual eagerly awaiting the availability of generic semaglutide. She recently lost her job and, without prescription coverage, is rationing her doses of Mounjaro, another GLP-1 medication.

Rogers describes the positive life changes she’s experienced while using medication. She hopes that once generic versions are accessible, they will be affordable enough to support her health journey moving forward.

The ongoing dialogue surrounding the approval of generic Ozempic exemplifies a broader conversation about medication accessibility and healthcare affordability in Canada.